However, in recent years, the introduction of new small molecules such as the B-cell lymphoma 2 (BCL2) inhibitor and the B-cell receptor pathway known as the Bruton tyrosine kinase (BTK) inhibitor have enlarged the therapeutic arsenal available for patients with CLL [1,10,11,12,13]. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.